1.Modern Expanded Application of Ancient Classic Formulae from the Perspective of Syndrome‑Formula Ontology Reconstruction
Guibin WANG ; Sijie LIN ; Zihan LIU ; Bo PANG
Journal of Traditional Chinese Medicine 2026;67(12):1251-1257
As the core carrier of the inheritance and innovation of traditional Chinese medicine (TCM), the modern expanded application of classic formulae is an inevitable trend for TCM to adapt to the changes in disease spectrum and achieve academic development. However, several challenges remain, including the vague definition of syndrome-formula ontology between ancient and modern times, the insufficient adaptability of the evidence grading system, and the disconnection between theory and clinical practice, having severely restricted the precise application and standardized development of classic formulae. Based on the current status of the modern expanded application of classic formulae, and grounded in the core theory of formula-syndrome correspondence in TCM, this paper constructs a theoretical framework of "syndrome-formula ontology reconstruction". The framework systematically expounds its core connotations, theoretical foundations and practical logic, and further clarifies the reconstruction direction of the TCM-specific evidence grading system by taking correspondence between formula and syndrome as the core, constructing a multi-dimensional and integrated evaluation framework, and adhering to the orientation of clinical application. The ultimate goal is to form a theoretical paradigm characterized by "syndrome-formula ontology reconstruction-evidence grading reconstruction-precise clinical application", thereby providing theoretical support for the digital inheritance, evidence-based development, and modern application of classical prescriptions.
2.Efficacy and Mechanism of Shenling Qushi Prescription in Treatment of Hyperuricaemia Mice
Xuan LIU ; Jialu QUE ; Caixia PANG ; Shuhui TAN ; Luyu CHEN ; Yihuan LI ; Xiaofeng LIN ; Qi LIANG ; Cuiling LIU
Chinese Journal of Experimental Traditional Medical Formulae 2026;32(19):197-206
ObjectiveTo investigate the urate-lowering effect of Shenling Qushi prescription in the mouse model of hyperuricaemia. MethodsSixty-three C57BL/6N mice were randomly assigned to the following groups (n=9): Control, model, low-dose (6 g·kg-1) Shenling Qushi prescription, medium-dose (12 g·kg-1) Shenling Qushi prescription, high-dose (24 g·kg-1) Shenling Qushi prescription, medium-dose Shenling Qushi prescription plus febuxostat (12+0.003 g·kg-1), and febuxostat (3 mg·kg-1). A mouse model of persistent hyperuricaemia was established via intraperitoneal injection of potassium oxazolamide (250 mg·kg-1) combined with oral administration of allopurinol (300 mg·kg-1) over a 28-day period. Concurrently, the prescription was administered orally at the specified doses once daily for 21 consecutive days. Throughout the experiment, mouse body weight, food intake, water consumption, and urine output were measured and recorded. Kidney and liver indices were calculated. Renal histopathological changes were observed by haematoxylin and eosin staining. Serum uric acid (SUA) and urinary uric acid (UUA) levels, along with xanthine oxidase (XOD) and adenosine deaminase (ADA), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, were determined. Real-time PCR was employed to assess the mRNA levels of urate anion transporter 1 (URAT1) and glucose transporter 9 (GLUT9) in the renal tissue, alongside those of XOD and ADA in the liver tissue. The protein levels of URAT1 and GLUT9 in the renal tissue were determined by Western blot. ResultsCompared with the normal group, model mice exhibited reduced food intake and body weight (P<0.01), decreased water consumption yet increased urine output, no significant change in the liver index but increased kidney index (P<0.01). Pathological findings revealed renal tissue damage including glomerular atrophy, epithelial cell detachment, and inflammatory cell infiltration. Furthermore, the model group exhibited elevated UUA and SUA levels (P<0.01), enhanced activities of ALT, AST, XOD, and ADA in the liver tissue (P<0.05, P<0.01), upregulated mRNA and protein levels of URAT1 and GLUT9 in the renal tissue (P<0.05), alongside markedly elevated mRNA levels of XOD and ADA in the liver (P<0.01). Compared with the model group, the Shenling Qushi prescription groups showed no significant changes in body weight or food intake, with water consumption and urine output remaining within normal ranges, alleviated glomerular atrophy, with reduced pathological damage such as inflammatory infiltration, declined UUA and SUA levels (P<0.01), and increased activities of ALT, AST, XOD, and ADA in the serum (P<0.01). Real-time PCR results demonstrated that Shenling Qushi prescription downregulated the mRNA levels of URAT1 and GLUT9 in the renal tissue (P<0.05, P<0.01) and XOD and ADA in the hepatic tissue (P<0.05, P<0.01). Western blot results demonstrated Shenling Qushi prescription reduced the protein levels of URAT1 and GLUT9 (P<0.05, P<0.01). ConclusionShenling Qushi prescription modulates fluid balance and reduces uric acid levels, thereby alleviating renal injury in hyperuricaemic mice. This effect is highly likely mediated through inhibition of uric acid synthesis and reabsorption.
3.Survival analysis of HIV/AIDS cases receiving anti-retroviral therapy in Weinan City from 2004 to 2023
PANG Lin ; XU Leitao ; LIU Longzhu
Journal of Preventive Medicine 2026;38(2):176-180
Objective:
To investigate the survival status and influencing factors of people living with HIV/AIDS receiving anti-retroviral therapy (ART) ≥5 years in Weinan City, Shaanxi Province from 2004 to 2023, so as to provide the evidence for improving ART effects and quality of life of HIV/AIDS cases.
Methods:
Baseline data including age, CD4+ T lymphocyte (CD4 cell) count, and viral load, as well as follow-up data including death time and cause of death of HIV/AIDS cases aged ≥18 years receiving ART ≥5 years in Weinan City from 2004 to 2023 were collected through the China AIDS Comprehensive Response Information System. The time when HIV/AIDS cases received ART ≥5 years was taken as the starting point, and death from AIDS-related diseases was taken as the outcome. The follow-up end time was December 31, 2023. Multivariable Cox proportional hazards regression model was used to analyze the influencing factors for survival time of ART HIV/AIDS cases.
Results:
A total of 1 015 HIV/AIDS cases were included. The median age was 30.00 (interquartile range, 6.00) years. There were 874 males (86.11%) and 141 females (13.89%). As of December 31, 2023, 175 cases died, including 104 deaths due to AIDS-related diseases, with a case fatality rate of 10.25%. The median survival time was 110.48 (interquartile range, 7.89) months. Multivariable Cox proportional hazards regression analysis showed that the risk of death was lower in ART HIV/AIDS cases with homosexual contact infection (HR=0.486, 95%CI: 0.343-0.687), second-line treatment regimens (HR=0.263, 95%CI: 0.152-0.455), and CD4 cell count ≥200 cells/μL (200-<500 cells/μL, HR=0.209, 95%CI: 0.147-0.298; ≥500 cells/μL, HR=0.076, 95%CI: 0.044-0.132). The risk of death was higher in ART HIV/AIDS cases with viral load ≥1 000 copies/mL (HR=2.508, 95%CI: 1.774-3.546).
Conclusions
The survival time of HIV/AIDS cases receiving ART ≥5 years in Weinan City was mainly affected by route of infection, treatment regimen, CD4 cell count, and viral load. It is recommended to strengthen the monitoring and management of cases with high viral load, and carry out interventions for populations with different routes of infection, so as to reduce the case fatality rate and prolong survival time.
4.Association analysis between sociodemographic factors and medication adherence among adolescents with mood disorders
Zheng YANG ; Xu TANG ; Zhixiong LIN ; Yanyan MO ; Chaozhu PANG ; Haiying ZHONG ; Xiaowen ZHU
Sichuan Mental Health 2026;39(5):408-414
BackgroundMedication non-adherence is a prominent problem among adolescent patients with mood disorders. However, the evidence base regarding factors associated with medication adherence in this population remains limited, and existing studies have yielded inconsistent findings on the direction and magnitude of the effects of sociodemographic factors on medication adherence. Empirical data on medication adherence among adolescent patients with mood disorders in Chinese population are still lacking. ObjectiveTo explore the association between sociodemographic factors and medication adherence among adolescent patients with mood disorders, and to provide references for disease management and the development of adherence-promoting interventions for this population. MethodsA total of 198 adolescent patients with mood disorders who attended the outpatient clinic of the Department of Psychiatry and Psychology at the Affiliated Hospital of Guangdong Medical University from February to July 2025 were enrolled in this study. Medication adherence was assessed using the Eight‑item Morisky Medication Adherence Scale (MMAS-8). Between-group comparisons were performed using nonparametric tests, and the Holm method was applied for correction in multiple comparisons. The variance inflation factor (VIF) was used to test multicollinearity. Ordinal Logistic regression was performed to analyze the independent influencing factors of medication adherence, and the parallel lines test was used to verify the model assumptions. ResultsAmong the 198 patients, the MMAS-8 score was (4.23±2.30), and poor medication adherence was detected in 140 patients (70.71%). The adjusted results of univariate analysis showed that there were no statistically significant differences in medication adherence among patients with respect to different genders, single-parent family status, paternal educational level, or maternal occupation (P>0.05). Ordinal Logistic regression analysis indicated that male gender was associated with a higher level of medication adherence(OR=2.592, 95% CI: 1.252–5.363, P=0.010), while maternal self-employment was associated with a lower level of medication adherence(OR=0.174, 95% CI: 0.039–0.769, P=0.021). ConclusionThe overall level of medication adherence among adolescents with mood disorders is relatively low. Male sex may be a protective factor for medication adherence in this population, while maternal self-employment may be a risk factor for medication adherence.
5.Safety, dosimetry, and efficacy of an optimized long-acting somatostatin analog for peptide receptor radionuclide therapy in metastatic neuroendocrine tumors: From preclinical testing to first-in-human study.
Wei GUO ; Xuejun WEN ; Yuhang CHEN ; Tianzhi ZHAO ; Jia LIU ; Yucen TAO ; Hao FU ; Hongjian WANG ; Weizhi XU ; Yizhen PANG ; Liang ZHAO ; Jingxiong HUANG ; Pengfei XU ; Zhide GUO ; Weibing MIAO ; Jingjing ZHANG ; Xiaoyuan CHEN ; Haojun CHEN
Acta Pharmaceutica Sinica B 2025;15(2):707-721
Peptide receptor radionuclide therapy (PRRT) with radiolabeled SSTR2 agonists is a treatment option that is highly effective in controlling metastatic and progressive neuroendocrine tumors (NETs). Previous studies have shown that an SSTR2 agonist combined with albumin binding moiety Evans blue (denoted as 177Lu-EB-TATE) is characterized by a higher tumor uptake and residence time in preclinical models and in patients with metastatic NETs. This study aimed to enhance the in vivo stability, pharmacokinetics, and pharmacodynamics of 177Lu-EB-TATE by replacing the maleimide-thiol group with a polyethylene glycol chain, resulting in a novel EB conjugated SSTR2-targeting radiopharmaceutical, 177Lu-LNC1010, for PRRT. In preclinical studies, 177Lu-LNC1010 exhibited good stability and SSTR2-binding affinity in AR42J tumor cells and enhanced uptake and prolonged retention in AR42J tumor xenografts. Thereafter, we presented the first-in-human dose escalation study of 177Lu-LNC1010 in patients with advanced/metastatic NETs. 177Lu-LNC1010 was well-tolerated by all patients, with minor adverse effects, and exhibited significant uptake and prolonged retention in tumor lesions, with higher tumor radiation doses than those of 177Lu-EB-TATE. Preliminary PRRT efficacy results showed an 83% disease control rate and a 42% overall response rate after two 177Lu-LNC1010 treatment cycles. These encouraging findings warrant further investigations through multicenter, prospective, and randomized controlled trials.
6.Discovery of a potential hematologic malignancies therapy: Selective and potent HDAC7 PROTAC degrader targeting non-enzymatic function.
Yuheng JIN ; Xuxin QI ; Xiaoli YU ; Xirui CHENG ; Boya CHEN ; Mingfei WU ; Jingyu ZHANG ; Hao YIN ; Yang LU ; Yihui ZHOU ; Ao PANG ; Yushen LIN ; Li JIANG ; Qiuqiu SHI ; Shuangshuang GENG ; Yubo ZHOU ; Xiaojun YAO ; Linjie LI ; Haiting DUAN ; Jinxin CHE ; Ji CAO ; Qiaojun HE ; Xiaowu DONG
Acta Pharmaceutica Sinica B 2025;15(3):1659-1679
HDAC7, a member of class IIa HDACs, plays a pivotal regulatory role in tumor, immune, fibrosis, and angiogenesis, rendering it a potential therapeutic target. Nevertheless, due to the high similarity in the enzyme active sites of class IIa HDACs, inhibitors encounter challenges in discerning differences among them. Furthermore, the substitution of key residue in the active pocket of class IIa HDACs renders them pseudo-enzymes, leading to a limited impact of enzymatic inhibitors on their function. In this study, proteolysis targeting chimera (PROTAC) technology was employed to develop HDAC7 drugs. We developed an exceedingly selective HDAC7 PROTAC degrader B14 which showcased superior inhibitory effects on cell proliferation compared to TMP269 in various diffuse large B cell lymphoma (DLBCL) and acute myeloid leukemia (AML) cells. Subsequent investigations unveiled that B14 disrupts BCL6 forming a transcriptional inhibition complex by degrading HDAC7, thereby exerting proliferative inhibition in DLBCL. Our study broadened the understanding of the non-enzymatic functions of HDAC7 and underscored the importance of HDAC7 in the treatment of hematologic malignancies, particularly in DLBCL and AML.
7.Self-assembled and intestine-targeting florfenicol nano-micelles effectively inhibit drug-resistant Salmonella typhimurium, eradicate biofilm, and maintain intestinal homeostasis.
Runan ZUO ; Linran FU ; Wanjun PANG ; Lingqing KONG ; Liangyun WENG ; Zeyuan SUN ; Ruichao LI ; Shaoqi QU ; Lin LI
Journal of Pharmaceutical Analysis 2025;15(7):101226-101226
Antimicrobial resistance (AMR) is a growing public health crisis that requires innovative solutions. Emerging multidrug resistant (MDR) Salmonella typhimurium has raised concern for its effect on pathogenic infection and mortality in humans caused by enteric diseases. To combat these MDR Salmonella typhimurium pathogens, highly effective and broad-spectrum antibiotics such as flufenicol (FFC) need to be evaluated for their potent antibacterial activity against Salmonella typhimurium. However, the low solubility and low oral bioavailability of flufenicol need to be addressed to better combat AMR. In this work, we develop a novel nano-formulation, flufenicol nano-micelles (FTPPM), which are based on d-α-tocopherol polyethylene glycol 1,000 succinate (TPGS)/poloxamer 188 (P188), for the targeted treatment of biofilms formed by drug-resistant Salmonella typhimurium in the intestine. Herein, FTPPM were prepared via a thin film hydration method. The preparation process for the mixed micelles is simple and convenient compared with other existing nanodrug delivery systems, which can further decrease production costs. The optimized FTPPM demonstrated outstanding stability and sustained release. An evaluation of the in vivo anti-drug-resistant Salmonella typhimurium efficacy demonstrated that FTPPM showed a stronger efficacy (68.17 %) than did florfenicol-loaded TPGS polymer micelles (FTPM), flufenicol active pharmaceutical ingredients (FFC-API), and flufenicol commercially available medicine (FFC-CAM), and also exhibited outstanding biocompatibility. Notably, FTPPM also inhibited drug-resistant Salmonella typhimurium from forming biofilms. More importantly, FTPPM effectively restored intestinal flora disorders induced by drug-resistant Salmonella typhimurium in mice. In summary, FTPPM significantly improved the solubility and oral bioavailability of florfenicol, enhancing its efficacy against drug-resistant Salmonella typhimurium both in vitro and in vivo. FTPPM represent a promising drug-resistant Salmonella typhimurium treatment for curbing bacterial resistance via oral administration.
8.Evaluation and Factor Analysis of Preoperative Medication-Related Issues in Patients Undergoing Video-Assisted Thoracoscopic Surgery
Yingkun LIU ; Ning PANG ; Chaoqun MA ; Rongrong FAN ; Yi LIU ; Yanguo LIU ; Lin HUANG ; Xiaohong ZHANG
Herald of Medicine 2025;44(5):764-770
Objective To evaluate drug-related problems(DRPs)and to analyze the influencing factors of patients un-dergoing video-assisted thoracoscopic surgery(VATS)before operation in thoracic surgery.Methods Clinical pharmacists used the Pharmaceutical Care Network Europe(PCNE)classification system(version 9.1)to analyze DRPs and influencing fac-tors of patients who received VATS from March 1 to May 31,2023,and had at least one comorbidity.Results Out of 300 pa-tients,174 were involved in a total of 200 DRPs.The most common category of DRPs is treatment safety(47.50%),followed by treatment effectiveness(46.00%)and others(6.50%).The most common cause of the problem is drug selection(33.83%),fol-lowed by other(33.33%)and patient cause(19.90%).367 interventions were conducted for DRPs,with the most interventions being at the drug level(55.86%),followed by the doctor level(39.24%)and the patient level(3.54%).In the end,96.00%of the intervention plan was accepted,and 86.50%of the problems were resolved.There were significant differences(P<0.05)in the number of underlying diseases,medication varieties,body mass index(BMI),and length of hospital stay between the group with and without DRPs.The results of multivariate analysis showed that comorbidities,number of medication types,and BMI were independent risk factors for preoperative occurrence(or potential)of DRPs in VATS patients in thoracic surgery(OR>1,P<0.05).Conclusions Clinical pharmacists can effectively evaluate preoperative DRPs in patients undergoing VATS in thoracic surgery through the PCNE classification system.Comorbidities,number of medications,and BMI are influential factors for the oc-currence of preoperative DRPs.Future clinical practice should focus on these risk factors to optimize treatment strategies and re-duce the occurrence of DRPs.
9.Comparison of three methods for induction of model mice with diminished ovarian reserve
Huadan LIN ; Xu WANG ; Chunhong CHEN ; Yuzhuo WEI ; Yanchun LUO ; Fanghui PANG ; Qiuyun QIN ; Ziyun RUAN
Chinese Journal of Comparative Medicine 2025;35(5):51-59
Objective To compare the effects of Tripterygium wilfordii polyglycosides,cyclophosphamide,and cisplatin on the establishment of a mouse model of diminished ovarian reserve(DOR).Methods Mice were randomly divided into the following treatment groups:control(Ctrl),Tripterygium wilfordii polyglycosides(TWP),cyclophosphamide(CTX),and cisplatin(DDP).Mice in the TWP group received a 50 mg/kg suspension of Tripterygium wilfordii polyglycosides by gavage for 14 days,mice in the CTX group received a 20 mg/kg cyclophosphamide suspension by intraperitoneal injection for 14 days,and mice in the DDP group received a 1.5 mg/kg cisplatin solution by intraperitoneal injection for 14 days.The body weight,uterine index,and ovarian index were recorded,the estrous cycle was monitored using the vaginal smear method,and the levels of anti-Mullerian hormone(AMH),estradiol(E2),follicle stimulating hormone(FSH),and luteinizing hormone(LH)were detected using ELISA.Hematoxylin and eosin staining was used to detect ovarian follicle development.The rates of oocyte maturation and fertility were analyzed.Results The three treatment groups of mice all showed the following:significantly decreased body weight and ovarian index(P<0.05);apparent disorder of the estrous cycle;significantly decreased levels of AMH and E2(P<0.05);decreased and increased rates of developing follicles and atretic follicles,respectively(P<0.05);and significantly decreased rates of oocyte maturation,pregnancy,and live birth(P<0.05).Conclusions DOR mouse models were successfully constructed using Tripterygium wilfordii polyglycosides,cyclophosphamide,or cisplatin,as evidenced by decreased body weight and ovarian index,disordered estrous cycle and hormones,and DOR function,resulting in reduced rates of oocyte maturation,pregnancy,and total number of live births.These DOR effects were most appropriate in the cyclophosphamide group.
10.Self-assembled and intestine-targeting florfenicol nano-micelles effectively inhibit drug-resistant Salmonella typhimurium,eradicate biofilm,and maintain intestinal homeostasis
Runan ZUO ; Linran FU ; Wanjun PANG ; Lingqing KONG ; Liangyun WENG ; Zeyuan SUN ; Ruichao LI ; Shaoqi QU ; Lin LI
Journal of Pharmaceutical Analysis 2025;15(7):1585-1605
Antimicrobial resistance(AMR)is a growing public health crisis that requires innovative solutions.Emerging multidrug resistant(MDR)Salmonella typhimurium has raised concern for its effect on path-ogenic infection and mortality in humans caused by enteric diseases.To combat these MDR Salmonella typhimurium pathogens,highly effective and broad-spectrum antibiotics such as flufenicol(FFC)need to be evaluated for their potent antibacterial activity against Salmonella typhimurium.However,the low solubility and low oral bioavailability of flufenicol need to be addressed to better combat AMR.In this work,we develop a novel nano-formulation,flufenicol nano-micelles(FTPPM),which are based on D-α-tocopherol polyethylene glycol 1,000 succinate(TPGS)/poloxamer 188(P188),for the targeted treatment of biofilms formed by drug-resistant Salmonella typhimurium in the intestine.Herein,FTPPM were prepared via a thin film hydration method.The preparation process for the mixed micelles is simple and convenient compared with other existing nanodrug delivery systems,which can further decrease pro-duction costs.The optimized FTPPM demonstrated outstanding stability and sustained release.An evaluation of the in vivo anti-drug-resistant Salmonella typhimurium efficacy demonstrated that FTPPM showed a stronger efficacy(68.17%)than did florfenicol-loaded TPGS polymer micelles(FTPM),flufenicol active pharmaceutical ingredients(FFC-API),and flufenicol commercially available medicine(FFC-CAM),and also exhibited outstanding biocompatibility.Notably,FTPPM also inhibited drug-resistant Salmonella typhimurium from forming biofilms.More importantly,FTPPM effectively restored intestinal flora dis-orders induced by drug-resistant Salmonella typhimurium in mice.In summary,FTPPM significantly improved the solubility and oral bioavailability of florfenicol,enhancing its efficacy against drug-resistant Salmonella typhimurium both in vitro and in vivo.FTPPM represent a promising drug-resistant Salmonella typhimurium treatment for curbing bacterial resistance via oral administration.


Result Analysis
Print
Save
E-mail